XML 30 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated statements of stockholders' equity - USD ($)
$ in Thousands
Total
Non-voting convertible preferred stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Beginning balance at Dec. 31, 2017 $ 98,887     $ 297,459 $ (198,502) $ (70)
Beginning balance, shares at Dec. 31, 2017     23,472,430      
Options exercised 602     602    
Options exercised, shares     64,938      
Stock-based compensation (Note 6(c)) 3,861     3,861    
Other comprehensive income 70         70
Net loss (26,698)       (26,698)  
Ending balance at Sep. 30, 2018 76,722     301,922 (225,200)  
Ending balance, shares at Sep. 30, 2018     23,537,368      
Beginning balance at Jun. 30, 2018 90,677     300,886 (210,207) (2)
Beginning balance, shares at Jun. 30, 2018     23,537,368      
Stock-based compensation (Note 6(c)) 1,036     1,036    
Other comprehensive income 2         $ 2
Net loss (14,993)       (14,993)  
Ending balance at Sep. 30, 2018 76,722     301,922 (225,200)  
Ending balance, shares at Sep. 30, 2018     23,537,368      
Beginning balance at Dec. 31, 2018 72,672     302,759 (230,087)  
Beginning balance, shares at Dec. 31, 2018     23,537,368      
Issuance of common stock for Former Neoleukin common stock (Note 3) 15,055     15,055    
Issuance of common stock for Former Neoleukin common stock (Note 3), shares     4,589,771      
Issuance of convertible preferred stock for Former Neoleukin common stock (Note 3) 33,432     33,432    
Issuance of convertible preferred stock for Former Neoleukin common stock (Note 3), shares   101,927        
Options exercised $ 40     40    
Options exercised, shares 13,104   13,104      
Stock-based compensation (Note 6(c)) $ 7,017     7,017    
Net loss (61,341)       (61,341)  
Ending balance at Sep. 30, 2019 66,875     358,303 (291,428)  
Ending balance, shares at Sep. 30, 2019   101,927 28,140,243      
Beginning balance at Jun. 30, 2019 72,329     304,625 (232,296)  
Beginning balance, shares at Jun. 30, 2019     23,537,368      
Issuance of common stock for Former Neoleukin common stock (Note 3) 15,055     15,055    
Issuance of common stock for Former Neoleukin common stock (Note 3), shares     4,589,771      
Issuance of convertible preferred stock for Former Neoleukin common stock (Note 3) 33,432     33,432    
Issuance of convertible preferred stock for Former Neoleukin common stock (Note 3), shares   101,927        
Options exercised $ 40     40    
Options exercised, shares 13,104   13,104      
Stock-based compensation (Note 6(c)) $ 5,151     5,151    
Net loss (59,132)       (59,132)  
Ending balance at Sep. 30, 2019 $ 66,875     $ 358,303 $ (291,428)  
Ending balance, shares at Sep. 30, 2019   101,927 28,140,243